false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP06.03. Clinical Impact of EGFR vs KRAS Mutations ...
EP06.03. Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma - PDF(Slides)
Back to course
Pdf Summary
This study compared the clinical outcomes of patients with EGFR and KRAS mutations in multifocal lung adenocarcinoma. The researchers analyzed data from 241 patients who underwent surgery for EGFR (n=150) and KRAS (n=91) adenocarcinomas between 2008 and 2022. The study found that 70.7% of EGFR tumors and 30.8% of KRAS tumors were subsolid. In addition, 56% of both EGFR and KRAS tumors were multifocal.<br /><br />The results showed that patients with KRAS mutations had a higher prevalence of smoking history, larger dominant tumor size, higher stage, higher SUVmax, higher tumor mutation burden, and worse disease-free survival and overall survival compared to those with EGFR mutations. When specifically looking at patients with multifocal disease, there was a trend towards a difference in overall survival between EGFR and KRAS mutations, although it was not statistically significant.<br /><br />Furthermore, for patients with traceable multifocal disease, the median follow-up of unresected secondary nodules was 55 months. The study found that survival without progression of secondary nodules was significantly shorter for patients with KRAS mutations compared to those with EGFR mutations.<br /><br />Univariate analysis showed that dominant tumor size, tumor morphology, pStage, and KRAS mutations were significantly associated with progression-free survival of secondary nodules. However, multivariate analysis revealed that only KRAS mutation was independently associated with worse progression-free survival of secondary nodules.<br /><br />In conclusion, this study suggests that patients with KRAS mutations in multifocal lung adenocarcinoma have a worse prognosis compared to those with EGFR mutations. Secondary nodules also progress faster in patients with KRAS mutations. Therefore, patients with KRAS multifocal disease should anticipate a higher likelihood of requiring treatment for secondary nodules.
Asset Subtitle
Jiahao Jiang
Meta Tag
Speaker
Jiahao Jiang
Topic
Pathology & Biomarkers: Genetic Biomarkers
Keywords
clinical outcomes
EGFR mutations
KRAS mutations
multifocal lung adenocarcinoma
subsolid tumors
multifocal tumors
disease-free survival
overall survival
secondary nodules
prognosis
×
Please select your language
1
English